Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
eNq1mF1v2jAUhu/5FVHuSYABTadAtTG6IbUa40ObdoNMcgCz1E79wcd+/RxCNZictTj4kti859jn9eMjh3e7p8TZAOOYko5b92quAySiMSbLjjud3FcD965bCddog06nBV5tVg/qrhMliPOOm417c0CEez8eHz6BUgDmditOSOdriMTZPClw4n1BfPWI0myOE24ojp0nECsad9xUisNXJ+SCqTy6W8p+8RRFEPrHL6ej61nz9HvoZ2JvUJUc2AMiS60oECPNSDIGRPSQgCVle630Ipo1gpt2rRYYhcB8BJxKFsEQidWQ0Q2OIdZHQgkHoyCLbTwGtklAZEG04v46euJG4miNdiN4HuiT/qBGe2InqrVqvd1qBM1287bRarWNQrGTrdKbRy3Cj2b1RrPevr0xLMiQMoESS6XAvHduKktxGDy/WvIY8zRBe2/NU9OtQgypYWDq6NtbSLaCCVMwStSe/aNPZJL4F2Y9PaLCUsYZiXpUElFAjOnYdCN6lAjYFVfUDHJid/QiBn492d+U6AE/lPMER6YcU6SRwMV0NCjGWGkCfEQcpsweAr5jEtMtvz5aTktpKfv0QMf/XIXNIAiMz81P5ZqCm6QvGU3BV8jBvAxJBmRByzJEGVEv9WLDcg489DI0QgkUdDMzQ4Yo6700X9bMbe/g5ANa0c/9iaknvklg+/Hhp1Yax51y1YxsUFs5sDDxy/2cH+o39LnN4F3DzNJMz4yVECl/7/vb7dZbIV7lSG2Wt2DXAfnJhWmvtbZyK+ddSo5DS6nP81vusrKYnrLX7u2yvejx/8eeVxtDMAklapED2Ro2B/3rk/hvI2ot7eEZOeyFOTSNSGBKbPU1cq5VLIugAblnChBfFwtc8OJR6MvQz19bupXQz15aupU/s2/Xwg==
EsxFWcnzLEWyGUVd
Listen
